ASR Vermogensbeheer N.V. Cuts Stock Holdings in DaVita Inc. $DVA

ASR Vermogensbeheer N.V. reduced its position in shares of DaVita Inc. (NYSE:DVA) by 9.4% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 15,000 shares of the company’s stock after selling 1,564 shares during the period. ASR Vermogensbeheer N.V.’s holdings in DaVita were worth $2,137,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Invesco Ltd. increased its stake in DaVita by 3.4% during the 1st quarter. Invesco Ltd. now owns 1,642,947 shares of the company’s stock worth $251,322,000 after buying an additional 53,402 shares in the last quarter. Northern Trust Corp increased its stake in DaVita by 20.2% during the 1st quarter. Northern Trust Corp now owns 890,632 shares of the company’s stock worth $136,240,000 after buying an additional 149,858 shares in the last quarter. Gates Capital Management Inc. increased its stake in DaVita by 0.7% during the 1st quarter. Gates Capital Management Inc. now owns 722,205 shares of the company’s stock worth $110,476,000 after buying an additional 4,698 shares in the last quarter. Amundi increased its stake in DaVita by 16.0% during the 1st quarter. Amundi now owns 517,690 shares of the company’s stock worth $79,584,000 after buying an additional 71,304 shares in the last quarter. Finally, Epoch Investment Partners Inc. increased its stake in DaVita by 10.7% during the 1st quarter. Epoch Investment Partners Inc. now owns 407,921 shares of the company’s stock worth $62,400,000 after buying an additional 39,485 shares in the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Stock Performance

DVA opened at $131.05 on Friday. DaVita Inc. has a one year low of $126.07 and a one year high of $179.60. The stock has a market capitalization of $9.37 billion, a PE ratio of 12.89, a P/E/G ratio of 0.94 and a beta of 1.13. The business’s 50 day moving average price is $134.81 and its 200 day moving average price is $140.03.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, August 5th. The company reported $2.95 EPS for the quarter, beating analysts’ consensus estimates of $2.70 by $0.25. DaVita had a return on equity of 369.39% and a net margin of 6.35%.The firm had revenue of $3.38 billion for the quarter, compared to analysts’ expectations of $3.36 billion. During the same period in the prior year, the firm posted $2.00 earnings per share. The firm’s quarterly revenue was up 6.1% on a year-over-year basis. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. As a group, equities research analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider James O. Hearty sold 2,351 shares of the company’s stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total value of $352,650.00. Following the transaction, the insider directly owned 26,038 shares in the company, valued at approximately $3,905,700. This represents a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 1.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on DVA. Truist Financial set a $148.00 price objective on DaVita in a research note on Friday, August 8th. Bank of America dropped their price target on DaVita from $145.00 to $140.00 and set an “underperform” rating for the company in a research report on Wednesday, September 10th. Barclays dropped their price target on DaVita from $169.00 to $160.00 and set an “equal weight” rating for the company in a research report on Thursday, August 7th. Wall Street Zen upgraded DaVita from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of DaVita in a research report on Saturday, September 27th. Four research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average target price of $158.00.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.